XNASTNYA
Market cap110mUSD
Jan 17, Last price
1.40USD
1D
0.72%
1Q
-31.37%
IPO
-92.36%
Name
Tenaya Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-124m
L+0.34%
CFO
-102m
L-2.25%
Profile
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
IPO date
Jul 30, 2021
Employees
141
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 139,880 | 134,334 | |||
Unusual Expense (Income) | |||||
NOPBT | (139,880) | (134,334) | |||
NOPBT Margin | |||||
Operating Taxes | (2) | ||||
Tax Rate | |||||
NOPAT | (139,880) | (134,332) | |||
Net income | (124,084) 0.34% | (123,663) 77.54% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 3,868 | 77,387 | |||
BB yield | -1.62% | -85.89% | |||
| Debt | |||||
Debt current | 8,638 | 4,006 | |||
Long-term debt | 20,529 | 26,192 | |||
Deferred revenue | |||||
Other long-term liabilities | 253 | 228 | |||
Net debt | (75,475) | (191,735) | |||
| Cash flow | |||||
Cash from operating activities | (102,072) | (104,424) | |||
CAPEX | (1,239) | (20,630) | |||
Cash from investing activities | 48,715 | 83,652 | |||
Cash from financing activities | 4,049 | 77,767 | |||
FCF | (130,441) | (142,322) | |||
| Balance | |||||
Cash | 104,642 | 204,230 | |||
Long term investments | 17,703 | ||||
Excess cash | 104,642 | 221,933 | |||
Stockholders' equity | (403,381) | (279,569) | |||
Invested Capital | 559,801 | 538,272 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 73,786 | 44,824 | |||
Price | 3.24 61.19% | 2.01 -89.39% | |||
Market cap | 239,067 165.35% | 90,095 -88.49% | |||
EV | 163,592 | (101,640) | |||
EBITDA | (131,193) | (127,867) | |||
EV/EBITDA | 0.79 | ||||
Interest | 2 | ||||
Interest/NOPBT | |||||